This amazing group and I are proud to present our work at #GI24 Pts with HCC have lots of options and ☢️ EBRT has many roles (ablative, bridge, palliative) But there are A LOT of ways to define/deliver EBRT, and no consensus on what “ablative” RT means…

@BCLC_group BCLC 2025 update 🔝🔝 incorporates recent advances in the field of treatment recommendations for #HCC, such as #EBRT Amazing sessions and clinical scenarios discussion!!

BCLC 2025 update is live and introduces a new framework (CUSE) that aims to guide clinicians and patients through the many dilemmas encountered when making treatment decisions. Congrats to the @BCLC_group and thank you all, esp @ma5RN , for the opportunity to contribute!

🤨5,000 patients later Roche scraps its TIGIT 👇 https://t.co/eCbkDbp9K6

More disappointing news in #HCC: Adjuvant pembrolizumab failed to beat surveillance in the global P3 #KEYNOTE-937 trial (NCT03867084). Merck disclosed the negative result quietly in an SEC filing. Not unexpected after #IMbrave050

Happening tomorrow! FREE #RSSwebinar "Celiac Plexus Radiosurgery: A New Treatment Modality for Pancreatic Cancer Pain" on Tues, 6/17 at noon ET! @LawrenceYaacov @banu_atalar @the_RSS

Great new @AmCollegeGastro Guideline Highlights summarizing some key points on diagnosis and management of focal liver lesions Guideline: https://t.co/aMqhl2gdyi

Exciting to bring the tech to USA. I hope the lessons on proton are not repeated. Over 40,000 patients have been treated with carbon ion worldwide. Unclear what cancers this enhances your ability to treat. It is ok to bring new tech and do research with it and not claim it is

🚨Study activated! NRG GI-011: Ph 3 RCT of Dose-Escalated RT in Locally Advanced Pancreas Cancer (LAP100) Here's a short (7 min) video. Please consider enrolling & reach out w any q's. Thanks to the NIH, NCI, @NRGonc for supporting our work! https://t.co/mGQBZOxjxJ 🙏🙏🙏

https://t.co/hL2O9QwW50

AI creating malware, self-editing its code, and attempting to blackmail engineers all to keep from being shut down (in controlled simulations). Most sobering read about AI thus far: https://t.co/qeYluzhgLw

🚨ESOPEC, Patterns of Recurrence🚨 🔥DM is the predominant pattern of recurrence and a large driver of mortality (~30-50%) ⚠️Locoregional Recurrence Remains notable (~20%) 🧐 Wonder about combined (Chemo + CRT) 🧨 to build on D-FLOT or FLOT, ❓ with organ preservation #ASCO25

@KrishanJethwa @NEJM Unknown now is FLOT+IO vs Checkmate-577 and more specifically not even just IO for non-pCR but what about CRT+IO for all vs FLOT+IO? How can we build upon SANO foundation for patients who don’t want surgery also?

🚨MATTERHORN🚨 🔎948 pts Stage II-IVa G/GEJ Adenocarcinoma Ph3 RCT: Peri-op FLOT +/- Durva Durva associated with: ✅⬆️EFS2 67% vs. 59%, p<0.001 ✅⬆️pCR 19% vs. 7% BUT 🚫🔺OS2 76% vs. 70%, p=NS Full pub here in @NEJM : https://t.co/zJYLzJvEft #ASCO2025

Chemoradiotherapy and Local Excision vs Total Mesorectal Excision in T2-T3ab, N0, M0 Rectal Cancer: The TAUTEM Randomized Clinical Trial ⁦@JAMASurgery⁩

#ASCO25: In pts with 5–20 brain mets, Phase 3 trial shows SRS/SRT leads to significantly better QoL vs HA-WBRT (↓ symptoms & interference, p<0.001), with no OS difference (8.3 vs 8.5 mo). SRS/SRT should be new SoC in this setting. #radonc 🔗

Well done - Sounds like a great opportunity for a clinical study!

We’ve been running a prospective study of low-dose RT for osteoarthritis, so several people have sent this article to me. Question for people doing this in the US: Are you billing 3D (as this study seems to do)? What organs need to be spared 50cGy/fx? https://t.co/1TJSvDRv2M

Great mid-week news on the publication front! Could it be that our GPC3-selective radiotheranostics agents aimed at #HCC could be repurposed for #NEPC? Fun collaboration with @sowalsky, @mishabeltran and Peter Nelson (@fredhutch)! Stay tuned! #radiopharmaceuticals

Very useful prospective cohort study with excellent PRO data: https://t.co/kyyk1qdCva Thanks @JCOOP_ASCO for the invitation to discuss palliative radiotherapy for incurable esophageal cancer:

Fantastic read on The “Linear Non-Thinking Model” this morning! Excellent take by @free_radical28 🏆🎯 Well worth the brief read! #radonc https://t.co/OlpT1VB1vi